A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis


Disclosures: BVH performed GSEA data analysis. BVH is a cofounder of and owns a significant financial stake in Novogenix Laboratories, LLC. All other authors report no potential conflicts of interest.

Contributions: OLF and TMM coordinated the research, performed experiments, analyzed and interpreted data, and participated in experimental design. SRM, IB, BVH, JSC, CS, KM, KRC, CB, EG, and PS performed experiments and analyzed data. AB and AJW, performed experiments. KA and VF assisted in data analysis. RJS, OLF, SRM, JSC and XBZ produced xenografts. SD and BVH participated in experimental design and provided conceptual advice. BVH performed GSEA data analysis. AB, SRM, ZG, and CS provided conceptual advice. CLM and RF provided patient samples and conceptual advice. XB and SD provided vital reagents. KJP, OLF, and TMM wrote the manuscript with assistance from KRC, SRM and JSC. KJP was the principal investigator. KJP and RJS developed the xenograft model, designed experiments, and analyzed and interpreted data and share primary responsibility for the paper.